Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy.
ACTA ACUST UNITED AC 2008;
5:487-91. [PMID:
18560388 DOI:
10.1038/ncponc1157]
[Citation(s) in RCA: 53] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2007] [Accepted: 02/22/2008] [Indexed: 01/01/2023]
Abstract
BACKGROUND
A 48-year-old man presented to a neurologist with complaints of bilateral hearing loss and tinnitus. The patient was a member of a large family affected by neurofibromatosis type 2 and first noted hearing loss 10 years before presentation.
INVESTIGATIONS
Medical and neurological examination, MRI scan of the brain and spinal cord, pure-tone audiometry, NU-6 monosyllabic word test with phoneme scoring, City University of New York topic-related sentences test, noise/voice test of minimal auditory capability battery.
DIAGNOSIS
Progressive neurofibromatosis-type-2-related vestibular schwannomas.
MANAGEMENT
Annual cranial MRI and audiology, surgical resection of right vestibular schwannoma, high-power behind-the-ear hearing aid, erlotinib therapy for progressive left vestibular schwannoma.
Collapse